Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Previous studies have described in vitro serial passage of a Deltagamma(1)34.5 herpes simplex virus type 1 (HSV-1) strain in SK-N-SH neuroblastoma cells and selection of mutants that have acquired the ability to infect and replicate in this previously nonpermissive cell line. Here we describe the selection of a mutant HSV-1 strain by in vivo serial passage, which prolongs survival in two separate experimental murine brain tumor models. Two conditionally replication-competent Deltagamma(1)34.5 viruses, M002, which expresses murine interleukin-12, and its parent virus, R3659, were serially passaged within human malignant glioma D54-MG cell lines in vitro or flank tumor xenografts in vivo. The major findings are (i) viruses passaged in vivo demonstrate decreased neurovirulence, whereas those passaged in vitro demonstrate a partial recovery of the neurovirulence associated with HSV-1; and (ii) vvD54-M002, the virus selected after in vivo serial passage of M002 in D54-MG tumors, improves survival in two independent murine brain tumor models compared to the parent (unpassaged) M002. Additionally, in vitro-passaged, but not in vivo-passaged, M002 displayed changes in the protein synthesis profile in previously nonpermissive cell lines, as well as early U(S)11 transcription. Thus, a mutant HSV-1 strain expressing a foreign gene can be selected for enhanced antitumor efficacy via in vivo serial passage within flank D54-MG tumor xenografts. The enhanced antitumor efficacy of vvD54-M002 is not due to restoration of protein synthesis or early U(S)11 expression. This finding emphasizes the contribution of the in vivo tumor environment for selecting novel oncolytic HSV specifically adapted for tumor cell destruction in vivo.
Shah
Amish C
AC
Division of Neurosurgery, University of Alabama at Birmingham, 510 20th Street South, Birmingham, AL 35294-3410, USA.
Price
Kathleen H
KH
Parker
Jacqueline N
JN
Samuel
Sharon L
SL
Meleth
Sreelatha
S
Cassady
Kevin A
KA
Gillespie
G Yancey
GY
Whitley
Richard J
RJ
Markert
James M
JM
D000818:Animals; D001932:Brain Neoplasms / Q000821:virology*; D002522:Chlorocebus aethiops; D003588:Cytopathogenic Effect, Viral; D005910:Glioma / Q000821:virology*; D018259:Herpesvirus 1, Human / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D018664:Interleukin-12 / Q000378:metabolism; D051379:Mice; D008805:Mice, Inbred A; D008808:Mice, Inbred CBA; D016513:Mice, SCID; D009154:Mutation / Q000235:genetics; D009374:Neoplasms, Experimental / Q000821:virology; D009447:Neuroblastoma / Q000378:metabolism / Q000628:therapy* / Q000821:virology; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D014709:Vero Cells; D014774:Virulence / Q000502:physiology*; D014779:Virus Replication
D018664:Interleukin-12